These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 12503485)
21. Are we living in the end of the blockbuster drug era? Debnath B; Al-Mawsawi LQ; Neamati N Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653 [TBL] [Abstract][Full Text] [Related]
22. Addressing Generic-Drug Market Failures - The Case for Establishing a Nonprofit Manufacturer. Liljenquist D; Bai G; Anderson GF N Engl J Med; 2018 May; 378(20):1857-1859. PubMed ID: 29768140 [No Abstract] [Full Text] [Related]
23. Therapeutic-class wars--drug promotion in a competitive marketplace. Kessler DA; Rose JL; Temple RJ; Schapiro R; Griffin JP N Engl J Med; 1994 Nov; 331(20):1350-3. PubMed ID: 7935706 [No Abstract] [Full Text] [Related]
24. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics". Zain S Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229 [No Abstract] [Full Text] [Related]
25. Branded drug reformulation: the next brand vs. generic antitrust battleground. Amoresano GV Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032 [No Abstract] [Full Text] [Related]
26. A few specialty drug prices fall--all generics. Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766 [No Abstract] [Full Text] [Related]
28. Angst about exclusivity: The potential cost of incentivizing makers of generic drugs. Chakradhar S; Khamsi R Nat Med; 2017 Oct; 23(10):1114-1116. PubMed ID: 28985215 [No Abstract] [Full Text] [Related]
29. The effect of generic competition on the price of brand-name drugs. Lexchin J Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552 [TBL] [Abstract][Full Text] [Related]
33. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry. Sinha MS; Curfman GD; Carrier MA JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104 [No Abstract] [Full Text] [Related]
34. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research]. Alván G Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017 [No Abstract] [Full Text] [Related]
35. White paper. The five myths of generic competition. A Pharma Matters report. March 2009. Drug News Perspect; 2009 Apr; 22(3):171-5. PubMed ID: 19440560 [TBL] [Abstract][Full Text] [Related]
36. Generics vs. patent drugs: a very Canadian debate, eh? Page B Can Oncol Nurs J; 1998 Feb; 8(1):2. PubMed ID: 9677919 [No Abstract] [Full Text] [Related]
38. The U.S. Medicine Chest: Implications of Increased Reliance on China. Gibson R Ann Intern Med; 2018 Dec; 169(12):873-874. PubMed ID: 30535133 [No Abstract] [Full Text] [Related]
39. Drug importation and safety of drugs obtained from Canada. Shepherd M Ann Pharmacother; 2007 Jul; 41(7):1288-91. PubMed ID: 17578879 [TBL] [Abstract][Full Text] [Related]
40. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response. Woolner D N Z Bioeth J; 2003 Oct; 4(3):22, 25-6. PubMed ID: 15597481 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]